Artículos de revistas
A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system
Fecha
2010Registro en:
TOXICON, v.56, n.7, Special Issue, p.1145-1154, 2010
0041-0101
10.1016/j.toxicon.2010.04.019
Autor
CHUDZINSKI-TAVASSI, Ana Marisa
DE-SA-JUNIOR, Paulo Luis
SIMONS, Simone Michaela
MARIA, Durvanei Augusto
VENTURA, Janaina de Souza
BATISTA, Isabel de Fatima Correia
FARIA, Fernanda
DURAES, Esther
REIS, Eduardo Moraes
DEMASI, Marilene
Institución
Resumen
The aim of this study was to evaluate the anti-tumor activity of Amblyomin-X, a serine protease Kunitz-type inhibitor. Amblyomin-X induced tumor mass regression and decreased number of metastatic events in a B16F10 murine melanoma model. Alterations on expression of several genes related to cell cycle were observed when two tumor cell lines were treated with Amblyomin-X. PSMB2, which encodes a proteasome subunit, was differentially expressed, in agreement to inhibition of proteasomal activity in both cell lines. In conclusion, our results indicate that Amblyomin-X selectively acts on tumor cells by inducing apoptotic cell death, possibly by targeting the ubiquitin-proteasome system. (C) 2010 Elsevier Ltd. All rights reserved.